Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model

  • Authors:
    • Hairong Xu
    • Xiaohui Niu
    • Qing Zhang
    • Lin Hao
    • Yi Ding
    • Weifeng Liu
    • Lu Yao
  • View Affiliations

  • Published online on: July 4, 2011     https://doi.org/10.3892/ol.2011.334
  • Pages: 773-778
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the last 15 years, chemotherapy-based therapeutic regimens for the treatment of osteosarcoma have failed to demonstrate improved survival rates. Novel approaches, including targeted therapy and antiangiogenic therapy, may provide new methods for the treatment of osteosarcoma, one of the most deadly malignant diseases. In the present study, the therapeutic efficacy of an endogenous angiogenesis inhibitor, endostatin, was tested in combination with the chemotherapeutic agent, adriamycin. BALB/c mice, aged 4-6 weeks were fed animal chow and had access to water ad libitum. The mice were divided into groups and injected with tumor cells. Immunohistochemical staining was performed to identify the microvessel density. The TUNEL technique was also used to determine the apoptotic index. The combination of endostatin and adriamycin produced marked synergistic antitumor activity in a mouse osteosarcoma model. These findings provide new guidelines for designing future clinical trials and for the application of currently available clinical drugs (endostatin has been approved for clinical use) in the treatment of osteosarcoma.

Related Articles

Journal Cover

September-October 2011
Volume 2 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xu H, Niu X, Zhang Q, Hao L, Ding Y, Liu W and Yao L: Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model. Oncol Lett 2: 773-778, 2011.
APA
Xu, H., Niu, X., Zhang, Q., Hao, L., Ding, Y., Liu, W., & Yao, L. (2011). Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model. Oncology Letters, 2, 773-778. https://doi.org/10.3892/ol.2011.334
MLA
Xu, H., Niu, X., Zhang, Q., Hao, L., Ding, Y., Liu, W., Yao, L."Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model". Oncology Letters 2.5 (2011): 773-778.
Chicago
Xu, H., Niu, X., Zhang, Q., Hao, L., Ding, Y., Liu, W., Yao, L."Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model". Oncology Letters 2, no. 5 (2011): 773-778. https://doi.org/10.3892/ol.2011.334